BioSpace News Archive

Theralase® Technologies Inc. is pleased to announce that Roger DuMoulin-White, B.Sc., P.Eng., Pro. Dir. has been appointed as President and Chief Executive Officer of the Company.

Neuronetics, Inc. announced that the management team will present at the William Blair 43rd Annual Growth Stock Conference on Wednesday, June 7, 2023.

DENTSPLY SIRONA Inc., announced that its Board of Directors declared a quarterly cash dividend of $0.14 per share of common stock, an indicated annual rate of $0.56 per share.

ImmunoGen, Inc. announced that Mark Enyedy, President and CEO, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference in New York, NY.

Gritstone bio, Inc. announced that the Compensation Committee of the company’s Board of Directors granted two employees nonqualified stock options to purchase an aggregate of 31,000 shares of its common stock with an exercise price of $1.96, which is equal to the closing price of Gritstone’s common stock on May 16, 2023, the date of the grant.

Biocept, Inc. announces the pricing of an underwritten public offering of 1,176,470 shares of its common stock and warrants to purchase up to an aggregate of 2,352,940 shares of its common stock at a combined offering price of $4.25 per share and an accompanying warrant to purchase two shares of common stock.

Accropeutics Bioscience announced that its oral small molecule TYK2/JAK1 inhibitor AC-201 has been approved by the Australian Human Research Ethics Committee to launch a clinical phase I trial in Australia.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of T cell receptor -engineered T cell therapies for the treatment of patients with cancer, announced that its Board of Directors has appointed Gavin MacBeath, Ph.D., as Chief Executive Officer of TScan and as a Class I Director of its Board, each effective as of May 24, 2023.

SI-BONE, Inc. announced that the company will be participating in the upcoming 2023 Jefferies Healthcare Conference in New York.

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, announced that management will present a company update at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 1:30pm Eastern Time.